Our ancillary clinical research projects are focused on discovery and validation of clinical biomarkers for Parkinson’s disease and to evaluate the effectiveness of the drugs that are being tested in our clinical trials.  There are currently no available biomarkers to conclusively diagnose the onset of Parkinson’s disease or to track its progression in people diagnosed with the disease. Our research is using multidisciplinary approaches to discover and confirm novel markers of disease onset and progression.